Dr. Meiqi Shi 史美祺
Chief Physician
Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical and comprehensive treatment of malignant tumors, chemotherapy for lung cancer and management of its complications, and standardized treatment of advanced lung cancer.
Dr. Shi is a Chief Physician at Jiangsu Cancer Hospital. Dr. Shi has conducted in-depth research on standardized treatment and recent advances in advanced lung cancer. Dr. Shi participated in two provincial-level research projects and multiple domestic and international clinical trials of new anti-cancer drugs.
Name order: in Chinese the family name comes first (Shi Meiqi). Papers usually list the name as Meiqi Shi or Shi M.
Selected publications
61 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Nat Commun, 2026 (senior author): Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM). PubMed 41554745
- J Thorac Dis, 2025 (first author): First-line serplulimab-based immunochemotherapy in elderly patients with extensive-stage small cell lung cancer: a multicenter, real-world study. PubMed 40529764
- Signal Transduct Target Ther, 2024 (first author): Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I/II study. PubMed 39389963
- Front Oncol, 2024 (senior author): Corrigendum: Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis. PubMed 38651145
- Lung Cancer (Auckl), 2023 (senior author): Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib. PubMed 37842288
- Front Oncol, 2023 (senior author): Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis. PubMed 37324026
- J Thorac Dis, 2020 (senior author): Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial. PubMed 32642151
- Curr Probl Cancer, 2019 (senior author): Comparative effectiveness study of single high-dose cisplatin with fractionated doses cisplatin in first-line therapy for treatment-naive Chinese patients with advanced non-small-cell lung cancer. PubMed 30777344
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion